{"title":"评估室特异性cd103阳性细胞对结直肠癌预后的预测作用。","authors":"Anpei Huang, Yuanhui Wu, Ji Cui, Muyan Cai, Yumo Xie, Jialin Zou, Maram Alenzi, Hui Yang, Pinzhu Huang, Meijin Huang","doi":"10.1007/s00262-025-04087-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>CD103<sup>+</sup> tissue-resident memory T cells was detected in various solid malignancies, like colorectal cancer (CRC), and associated with improved survival. However, clinical significance of CD103<sup>+</sup> cells in specific intratumor compartment remains unclear.</p><p><strong>Methods: </strong>The abundance and distribution of CD103<sup>+</sup> cells were assessed using immunohistochemistry and quantified separately for 3 compartments, including intraepithelial compartments at center of tumor (CT-IEL), stromal compartments at center of tumor (CT-ST) and invasive margin (IM) in a cohort of 224 CRC patients under radical surgery and correlated with outcome. Findings in each compartment were then validated in an external validation cohort comprising 294 CRC patients.</p><p><strong>Results: </strong>Elevated density of CD103<sup>+</sup> cells infiltration in the CT-IEL, CT-ST or IM compartment was correlated with favorable survival in both the initial discovery cohort and subsequent validation cohort. Notably, abundant CD103<sup>+</sup> cells located in the CT-IEL compartment was remained an independent prognostic indicator for CRC patients by multivariant analysis. Characterization study showed that intraepithelial CD103<sup>+</sup> cells were predominantly single positive CD8 T cells. Conversely, CD103<sup>+</sup> cells exhibited a heterogeneous population comprising CD103<sup>+</sup>CD8<sup>+</sup> cells, CD103<sup>+</sup>CD4<sup>+</sup> cells, and nonconventional CD103<sup>+</sup>CD4<sup>+</sup>CD8<sup>+</sup> cells in the CT-ST and IM compartments. Finally, a CD103 score was generated comprising abundance of CD103<sup>+</sup> cells in the 3 compartments. This score had the highest relative contribution to the risk of all clinical parameters for prognosis in both cohorts.</p><p><strong>Conclusion: </strong>This study supported a phenotypic heterogeneity of CD103<sup>+</sup> cells in CRC, and provided a reliable estimate of the risk of death and recurrence in CRC patients based on combined analysis of CD103<sup>+</sup> cells within 3 intratumor compartments.</p>","PeriodicalId":520581,"journal":{"name":"Cancer immunology, immunotherapy : CII","volume":"74 8","pages":"237"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12145388/pdf/","citationCount":"0","resultStr":"{\"title\":\"Assessment of compartment-specific CD103-positive cells for prognosis prediction of colorectal cancer.\",\"authors\":\"Anpei Huang, Yuanhui Wu, Ji Cui, Muyan Cai, Yumo Xie, Jialin Zou, Maram Alenzi, Hui Yang, Pinzhu Huang, Meijin Huang\",\"doi\":\"10.1007/s00262-025-04087-z\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>CD103<sup>+</sup> tissue-resident memory T cells was detected in various solid malignancies, like colorectal cancer (CRC), and associated with improved survival. However, clinical significance of CD103<sup>+</sup> cells in specific intratumor compartment remains unclear.</p><p><strong>Methods: </strong>The abundance and distribution of CD103<sup>+</sup> cells were assessed using immunohistochemistry and quantified separately for 3 compartments, including intraepithelial compartments at center of tumor (CT-IEL), stromal compartments at center of tumor (CT-ST) and invasive margin (IM) in a cohort of 224 CRC patients under radical surgery and correlated with outcome. Findings in each compartment were then validated in an external validation cohort comprising 294 CRC patients.</p><p><strong>Results: </strong>Elevated density of CD103<sup>+</sup> cells infiltration in the CT-IEL, CT-ST or IM compartment was correlated with favorable survival in both the initial discovery cohort and subsequent validation cohort. Notably, abundant CD103<sup>+</sup> cells located in the CT-IEL compartment was remained an independent prognostic indicator for CRC patients by multivariant analysis. Characterization study showed that intraepithelial CD103<sup>+</sup> cells were predominantly single positive CD8 T cells. Conversely, CD103<sup>+</sup> cells exhibited a heterogeneous population comprising CD103<sup>+</sup>CD8<sup>+</sup> cells, CD103<sup>+</sup>CD4<sup>+</sup> cells, and nonconventional CD103<sup>+</sup>CD4<sup>+</sup>CD8<sup>+</sup> cells in the CT-ST and IM compartments. Finally, a CD103 score was generated comprising abundance of CD103<sup>+</sup> cells in the 3 compartments. This score had the highest relative contribution to the risk of all clinical parameters for prognosis in both cohorts.</p><p><strong>Conclusion: </strong>This study supported a phenotypic heterogeneity of CD103<sup>+</sup> cells in CRC, and provided a reliable estimate of the risk of death and recurrence in CRC patients based on combined analysis of CD103<sup>+</sup> cells within 3 intratumor compartments.</p>\",\"PeriodicalId\":520581,\"journal\":{\"name\":\"Cancer immunology, immunotherapy : CII\",\"volume\":\"74 8\",\"pages\":\"237\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-06-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12145388/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer immunology, immunotherapy : CII\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s00262-025-04087-z\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer immunology, immunotherapy : CII","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s00262-025-04087-z","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Assessment of compartment-specific CD103-positive cells for prognosis prediction of colorectal cancer.
Background: CD103+ tissue-resident memory T cells was detected in various solid malignancies, like colorectal cancer (CRC), and associated with improved survival. However, clinical significance of CD103+ cells in specific intratumor compartment remains unclear.
Methods: The abundance and distribution of CD103+ cells were assessed using immunohistochemistry and quantified separately for 3 compartments, including intraepithelial compartments at center of tumor (CT-IEL), stromal compartments at center of tumor (CT-ST) and invasive margin (IM) in a cohort of 224 CRC patients under radical surgery and correlated with outcome. Findings in each compartment were then validated in an external validation cohort comprising 294 CRC patients.
Results: Elevated density of CD103+ cells infiltration in the CT-IEL, CT-ST or IM compartment was correlated with favorable survival in both the initial discovery cohort and subsequent validation cohort. Notably, abundant CD103+ cells located in the CT-IEL compartment was remained an independent prognostic indicator for CRC patients by multivariant analysis. Characterization study showed that intraepithelial CD103+ cells were predominantly single positive CD8 T cells. Conversely, CD103+ cells exhibited a heterogeneous population comprising CD103+CD8+ cells, CD103+CD4+ cells, and nonconventional CD103+CD4+CD8+ cells in the CT-ST and IM compartments. Finally, a CD103 score was generated comprising abundance of CD103+ cells in the 3 compartments. This score had the highest relative contribution to the risk of all clinical parameters for prognosis in both cohorts.
Conclusion: This study supported a phenotypic heterogeneity of CD103+ cells in CRC, and provided a reliable estimate of the risk of death and recurrence in CRC patients based on combined analysis of CD103+ cells within 3 intratumor compartments.